[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1990

Efficacy, Safety, and Quality-of-Life Assessment of Captopril Antihypertensive Therapy in Clinical Practice

Author Affiliations

From Rush-Presbyterian–St Luke's Medical Center, Chicago, Ill (Dr Schoenberger); Harvard School of Public Health and the Dana Farber Cancer Institute, Boston, Mass (Dr Testa); E. R. Squibb and Sons Inc, Princeton, NJ (Dr Ross); and the Philadelphia (Pa) Association for Clinical Trials (Ms Brennan and Dr Bannon).

Arch Intern Med. 1990;150(2):301-306. doi:10.1001/archinte.1990.00390140051011
Abstract

• Successful long-term treatment of hypertension must include consideration of individual patients' life-styles interfaced with the potential for adverse drug events. In a postmarketing surveillance study, 30 515 patients received captopril monotherapy and were evaluated by 7792 physicians. Mean systolic and diastolic blood pressures were reduced 17 and 11 mm Hg, respectively. Mean diastolic blood pressure was reduced 10% for patients with mild hypertension; larger mean reductions were noted for patients with moderate (16.5%) and severe (21.5%) hypertension. Captopril therapy was equally effective in all races (white, Hispanic, and black patients), age groups, and in isolated instances of systolic hypertension. Only 4.9% of patients reporting an adverse event required discontinuation of therapy. Headache (1.8%) and dizziness (1.6%) were the most frequently reported adverse events. Quality-of-life measures improved.

(Arch Intern Med. 1990;150:301-306)

×